Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
【Huadong Pharmaceutical Completed Two Phase Iii Clinical Trials Of The Innovative Topical Skin Preparation Rofloxate Cream To Enroll The First Patient】Recently, Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd. (“East China”), A Wholly-Owned Subsidiary Of Huadong Pharmaceutical Co., Ltd. (“East China”) Conducted A Multi-Center, Randomized, Double-Blind, Excipient-Controlled Phase Iii Bridging Study Evaluating The Efficacy And Safety Of 0.15% Rofloxate Cream (Zoryve) In Patients With Mild To Moderate Atopic Dermatitis, Completed The First Patient Enrollment And Administration At Huashan Hospital Affiliated To Fudan University In Shanghai; A Multi-Center, Randomized, Double-Blind, Excipient-Controlled Evaluation 0.3% Of Rofloxate Cream (Zoryve) Treatment Phase Iii Clinical Study On Efficacy And Safety Of Plaque Psoriasis In China Peking University People'S Hospital Completed Enrollment And Administration Of The First Test Subject. Rofloxate Cream Is An Innovative Topical Skin Formulation Product Introduced By China And The US Nasdaq Listed Company Arcutis In August 2023. China And US East China Have Exclusive Licenses For This Product In Greater China And Southeast Asia
Quick access to 24/7
Quick access to more editor-selected real-time news
Exclusive video for free
FastBull VIPject team is dedicated to create exclusive videos
Follow More Symbols
You can add more symbols to your watchlist.
More comprehensive macro data and economic indicators
More comprehensive historical data on indicators to help analyze macro markets
Member-only Database
Comprehensive forex, commodity, and equity market data